Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

193.02USD
8 May 2020
Change (% chg)

$0.03 (+0.02%)
Prev Close
$192.99
Open
$193.01
Day's High
$193.38
Day's Low
$191.64
Volume
4,208,109
Avg. Vol
1,314,681
52-wk High
$202.22
52-wk Low
$114.27

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

No Data Available
Sell Hold Buy

Overall

Beta: 1.20
Market Cap(Mil.): $63,659.11
Shares Outstanding(Mil.): 329.81
Dividend: 0.74
Yield (%): 1.53
Photo

Domino's Pizza to join S&P 500, despite pandemic's impact

Domino's Pizza Inc will join the Standard & Poor's 500 , despite having last month withdrawn its long-term growth outlook after closing stores because of the coronavirus pandemic.

Domino's Pizza to join S&P 500, despite pandemic's impact

May 6 Domino's Pizza Inc will join the Standard & Poor's 500, despite having last month withdrawn its long-term growth outlook after closing stores because of the coronavirus pandemic.

BRIEF-Abbvie Says Allergan CEO Brent Saunders Has Elected Not To Join Abbvie Board

* ABBVIE INC - ALLERGAN'S CURRENT CHAIRMAN AND CEO BRENT SAUNDERS HAS ELECTED NOT TO JOIN ABBVIE BOARD Source text: (https://bit.ly/2WrkrsY) Further company coverage:

PRESS DIGEST- Financial Times - May 6

May 6 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

UPDATE 2-AbbVie wins U.S. antitrust approval to buy Allergan

WASHINGTON, May 5 Drugmaker AbbVie Inc has won U.S. antitrust approval to buy Botox maker Allergan , a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday.

AbbVie wins U.S. antitrust approval to buy Allergan

WASHINGTON, May 5 Drugmaker AbbVie has won U.S. antitrust approval to buy Botox-maker Allergan, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday.

AbbVie sees substantial hit to Botox from pandemic, lowers Humira growth forecast

AbbVie Inc on Friday said it expects the coronavirus outbreak to substantially limit sales of Botox and similar aesthetic products that the U.S. drugmaker is set to acquire through its buyout of Allergan Plc .

BRIEF-Abbvie Says Saw Modest Impact To New Patient Starts For Some Drugs Due To COVID-19 Restrictions: Q1 Conf Call

* ABBVIE INC SAYS SAW MODEST IMPACT TO NEW PATIENT STARTS FOR SOME DRUGS DUE TO COVID-19 RESTRICTIONS IN Q1: CONF. CALL

AbbVie sees substantial hit to Botox from pandemic, lowers Humira growth forecast

AbbVie Inc on Friday said it expects the coronavirus outbreak to substantially limit sales of Botox and similar aesthetic products that the U.S. drugmaker is set to acquire through its buyout of Allergan Plc .

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.12%
Rohstoffe +0.08%
Industrie -0.08%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.10%
Finanzindustrie -0.03%
Pharma +0.06%
Technologie +0.22%
Telekommunikation -0.11%